WEIGAO GROUP (01066) announced that on April 30, 2026, its indirect wholly-owned subsidiary, Wego Healthcare Fund, acting as a limited partner, entered into a limited partnership agreement with WEIGAO (Hong Kong), among others, as the general partner. The agreement concerns the establishment of a fund with a proposed size of 529.65 billion Korean won (approximately RMB 243.6 million). The fund will primarily invest in small and medium-sized enterprises as well as mid-sized companies in Korea and overseas, with a focus on open innovation and international business expansion involving Korean and foreign companies, universities, and research institutions. Wego Healthcare Fund's proposed capital commitment will amount to 15.89 billion Korean won (around RMB 73.09 million), representing 30% of the fund’s total committed capital. The board believes that, as a leading large-scale enterprise in China's medical device industry, international expansion and technological innovation are crucial for the company to continuously enhance its competitiveness. The execution of the limited partnership agreement aims to strengthen the group’s global business layout, improve product innovation capabilities, and expand access to overseas markets. The fund’s primary investment scope and regions align closely with the company’s strategy to deepen research and development innovation, accelerate the construction of technology platforms, expand complementary product lines, and develop global market channels. By participating as a limited partner, the company will gain early access to promising technology platforms in the Asia-Pacific region and internationally, as well as opportunities to collaborate with clinically value-driven innovative enterprises. This is expected to enrich the group’s product pipeline, facilitate cost-effective acquisition of innovative technologies, and accelerate entry into new markets. Additionally, the investment offers potential for attractive long-term returns commensurate with the risk characteristics of venture capital. The fund adopts a dual general partner structure, jointly managed by SV Investment and WEIGAO (Hong Kong), a subsidiary of WEIGAO GROUP. This structure leverages the Korean general partner’s local industry networks, policy resources, and extensive investment experience, while retaining the WEIGAO Group’s expertise in cross-border project evaluation. Other limited partners in the fund are also leading enterprises in their respective industries, possessing high-quality resource networks in Korean and international markets. The company believes that participating in the fund will enable efficient use of existing financial resources, enhance potential capital gains, and accumulate substantial industrial resources. By leveraging the advantages of the local general partner, the group can swiftly enter key markets such as Korea, North America, and Southeast Asia, thereby improving its international operational capabilities. Furthermore, the fund’s allocation—approximately half to Korea and half to other overseas regions—helps mitigate risks associated with cyclical fluctuations in any single market.